Patents by Inventor Jackie SHENG

Jackie SHENG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240425611
    Abstract: Provided are trispecific T Cell Engagers or TSMAb's, antibodies that can simultaneously engage three different types of epitopes on the same target or on different targets. More specifically, the invention is directed to trispecific molecules that bind to DLL3, MUC17 or CLDN18.2 and activate CD (cluster of differentiation) molecules (e.g. CD3, CD28 and CD137). Also provided are methods of treating an ailment such as cancer using an antibody (or fragment) against DLL3, MUC17 or CLD18 paired with an antibody (or fragment) of an agonist antibody that activates CD3, CD28 and/or CD137.
    Type: Application
    Filed: June 28, 2024
    Publication date: December 26, 2024
    Inventors: Margaret KAROW, Richard Yau, Jackie SHENG
  • Publication number: 20240343827
    Abstract: Provided are bispecific T Cell Engagers. More specifically, the invention is directed to bispecific molecules that bind to DLL3, MUC17 or CLD18 and activate CD (cluster of differentiation) molecules (e.g. CD3, CD28 and CD137). Also provided are methods of treating an ailment such as cancer using an antibody (or fragment) against DLL3, MUC17 or CLD18 paired with an antibody (or fragment) of an agonist antibody that activates CD3, CD28 and/or CD137.
    Type: Application
    Filed: March 21, 2024
    Publication date: October 17, 2024
    Inventors: Margaret KAROW, Richard Yau, Jackie SHENG
  • Publication number: 20240279324
    Abstract: Multispecific antagonists for targeting angiogenesis pathways are disclosed. The multispecific antagonists may be used for the treatment of disorders associated with angiogenesis pathways.
    Type: Application
    Filed: June 2, 2022
    Publication date: August 22, 2024
    Inventors: Jackie SHENG, Tyler LIBAN, Gopal SAPPARAPU
  • Patent number: 12060434
    Abstract: Provided are trispecific T Cell Engagers or TSMAb's, antibodies that can simultaneously engage three different types of epitopes on the same target or on different targets. More specifically, the invention is directed to trispecific molecules that bind to DLL3, MUC17 or CLDN18.2 and activate CD (cluster of differentiation) molecules (e.g. CD3, CD28 and CD137). Also provided are methods of treating an ailment such as cancer using an antibody (or fragment) against DLL3, MUC17 or CLD18 paired with an antibody (or fragment) of an agonist antibody that activates CD3, CD28 and/or CD137.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: August 13, 2024
    Assignee: Gensun Biopharma Inc.
    Inventors: Margaret Karow, Richard Yau, Jackie Sheng
  • Patent number: 12018073
    Abstract: Antitumor antagonists that bind specifically to immune checkpoint regulators, angiogenesis pathway regulators and/or TGF pathway regulators are disclosed. Also disclosed are methods for treating proliferative disorders, infections, and immunological disorders with the antitumor antagonists described herein.
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: June 25, 2024
    Assignee: GENSUN BIOPHARMA, INC.
    Inventors: Margaret Karow, Jackie Sheng, Wei Zhang
  • Patent number: 11976133
    Abstract: Provided are bispecific T Cell Engagers. More specifically, the invention is directed to bispecific molecules that bind to DLL3, MUC17 or CLD18 and activate CD (cluster of differentiation) molecules (e.g. CD3, CD28 and CD137). Also provided are methods of treating an ailment such as cancer using an antibody (or fragment) against DLL3, MUC17 or CLD18 paired with an antibody (or fragment) of an agonist antibody that activates CD3, CD28 and/or CD137.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: May 7, 2024
    Assignee: Gensun Biopharma Inc.
    Inventors: Margaret Karow, Richard Yau, Jackie Sheng
  • Patent number: 11945873
    Abstract: Antitumor antagonists that bind specifically to immune checkpoint regulators, angiogenesis pathway regulators and/or TGF pathway regulators are disclosed. Also disclosed are methods for treating proliferative disorders, infections, and immunological disorders with the antitumor antagonists described herein.
    Type: Grant
    Filed: April 16, 2021
    Date of Patent: April 2, 2024
    Assignee: GENSUN BIOPHARMA, INC.
    Inventors: Jackie Sheng, Bo Liu, Margaret Karow
  • Patent number: 11851493
    Abstract: Antitumor antagonists that bind specifically to immune checkpoint regulator and/or components of the angiogenesis pathways and/or components of the TGF pathway are disclosed. Also disclosed is a method of treating proliferative disorders with the antitumor antagonists.
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: December 26, 2023
    Assignee: GENSUN BIOPHARMA, INC.
    Inventors: Jackie Sheng, Bo Liu
  • Publication number: 20230331857
    Abstract: Antitumor antagonists that bind specifically to immune checkpoint regulator are disclosed. Also disclosed is a method of treating proliferative disorders with the antitumor antagonists.
    Type: Application
    Filed: April 25, 2023
    Publication date: October 19, 2023
    Inventors: Jackie SHENG, Margaret KAROW, Wei ZHANG
  • Patent number: 11667716
    Abstract: Antitumor antagonists that bind specifically to immune checkpoint regulator are disclosed. Also disclosed is a method of treating proliferative disorders with the antitumor antagonists.
    Type: Grant
    Filed: February 20, 2020
    Date of Patent: June 6, 2023
    Assignee: Gensun Biopharma, Inc.
    Inventors: Jackie Sheng, Margaret Karow, Wei Zhang
  • Publication number: 20220389120
    Abstract: Multispecific antagonists for targeting angiogenesis pathways are disclosed. The multispecific antagonists may be used for the treatment of disorders associated with angiogenesis pathways.
    Type: Application
    Filed: June 2, 2022
    Publication date: December 8, 2022
    Inventors: Jackie SHENG, Gopal Sapparapu, Tyler Liban
  • Patent number: 11518813
    Abstract: Antitumor antagonists that bind specifically to immune checkpoint regulator and/or components of the angiogenesis pathways and/or components of the TGF pathway are disclosed. Also disclosed is a method of treating proliferative disorders with the antitumor antagonists.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: December 6, 2022
    Assignee: GENSUN BIOPHARMA, INC.
    Inventors: Jackie Sheng, Bo Liu
  • Publication number: 20210269551
    Abstract: Provided are trispecific T Cell Engagers or TSMAb's, antibodies that can simultaneously engage three different types of epitopes on the same target or on different targets. More specifically, the invention is directed to trispecific molecules that bind to DLL3, MUC17 or CLDN18.2 and activate CD (cluster of differentiation) molecules (e.g. CD3, CD28 and CD137). Also provided are methods of treating an ailment such as cancer using an antibody (or fragment) against DLL3, MUC17 or CLD18 paired with an antibody (or fragment) of an agonist antibody that activates CD3, CD28 and/or CD137.
    Type: Application
    Filed: February 1, 2021
    Publication date: September 2, 2021
    Applicant: Gensun Biopharma Inc.
    Inventors: Margaret Karow, Richard Yau, Jackie Sheng
  • Publication number: 20210246222
    Abstract: Provided are bispecific T Cell Engagers. More specifically, the invention is directed to bispecific molecules that bind to DLL3, MUC17 or CLD18 and activate CD (cluster of differentiation) molecules (e.g. CD3, CD28 and CD137). Also provided are methods of treating an ailment such as cancer using an antibody (or fragment) against DLL3, MUC17 or CLD18 paired with an antibody (or fragment) of an agonist antibody that activates CD3, CD28 and/or CD137.
    Type: Application
    Filed: February 1, 2021
    Publication date: August 12, 2021
    Applicant: Gensun Biopharma Inc.
    Inventors: Margaret Karow, Richard Yau, Jackie Sheng
  • Publication number: 20210246214
    Abstract: Antitumor antagonists that bind specifically to immune checkpoint regulators, angiogenesis pathway regulators and/or TGF pathway regulators are disclosed. Also disclosed are methods for treating proliferative disorders, infections, and immunological disorders with the antitumor antagonists described herein.
    Type: Application
    Filed: April 16, 2021
    Publication date: August 12, 2021
    Inventors: Jackie SHENG, Bo LIU, Margaret KAROW
  • Patent number: 11001635
    Abstract: Antitumor antagonists that bind specifically to immune checkpoint regulators, angiogenesis pathway regulators and/or TGF pathway regulators are disclosed. Also disclosed are methods for treating proliferative disorders, infections, and immunological disorders with the antitumor antagonists described herein.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: May 11, 2021
    Assignee: Gensun Biopharma Inc.
    Inventors: Jackie Sheng, Bo Liu, Margaret Karow
  • Publication number: 20210115123
    Abstract: A trispecific inhibitor for treating cancer includes a first targeting domain having a binding specificity conferred by a VEGF binding antagonist; a second targeting domain having a binding specificity conferred by an immune checkpoint regulator binding antagonist; and a third targeting domain having a binding specificity conferred by a Tie2 tyrosine kinase receptor binding antagonist. The targeting domains may contain one or more antibody variable regions, peptide inhibitors, dominant negative proteins, small molecule drugs or combinations thereof.
    Type: Application
    Filed: December 11, 2020
    Publication date: April 22, 2021
    Inventors: Jackie SHENG, BO LIU, HAIQUN JIA
  • Patent number: 10894823
    Abstract: A trispecific inhibitor for treating cancer includes a first targeting domain having a binding specificity conferred by a VEGF binding antagonist; a second targeting domain having a binding specificity conferred by an immune checkpoint regulator binding antagonist; and a third targeting domain having a binding specificity conferred by a Tie2 tyrosine kinase receptor binding antagonist. The targeting domains may contain one or more antibody variable regions, peptide inhibitors, dominant negative proteins, small molecule drugs or combinations thereof.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: January 19, 2021
    Assignee: GENSUN BIOPHARMA INC.
    Inventors: Jackie Sheng, Bo Liu, Haiqun Jia
  • Publication number: 20210009696
    Abstract: Antitumor antagonists that bind specifically to immune checkpoint regulator and/or components of the angiogenesis pathways and/or components of the TGF pathway are disclosed. Also disclosed is a method of treating proliferative disorders with the antitumor antagonists.
    Type: Application
    Filed: August 17, 2020
    Publication date: January 14, 2021
    Inventors: Jackie SHENG, Bo LIU
  • Publication number: 20210002348
    Abstract: Antitumor antagonists that bind specifically to immune checkpoint regulators, angiogenesis pathway regulators and/or TGF pathway regulators are disclosed. Also disclosed are methods for treating proliferative disorders, infections, and immunological disorders with the antitumor antagonists described herein.
    Type: Application
    Filed: August 17, 2020
    Publication date: January 7, 2021
    Inventors: Margaret Karow, Jackie Sheng, Wei Zhang